Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice

Research output: Contribution to journalArticle

822 Citations (Scopus)

Abstract

Background: In addition to the treatment of specific cardiovascular risk factors, intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. Methods: We did a randomised controlled open 2×2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events, in people with one or more of the following: hypertension, hypercholesterolaemia, diabetes, obesity, family history of premature myocardial infarction, or individuals who were elderly. Findings: 4495 people (2583 female, mean age 64-4 years) were included in the trial. After a mean follow-up of 3-6 years the trial was prematurely stopped on ethical grounds when newly available evidence from other trials on the benefit of aspirin in primary prevention was strictly consistent with the results of the second planned interim analysis. Aspirin lowered the frequency of all the endpoints, being significant for cardiovascular death (from 1.4 to 0.8%; relative risk 0.56 [95% Cl 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3%; 0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than the no-aspirin group (1.1% vs 0.3%: p

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalLancet
Volume357
Issue number9250
DOIs
Publication statusPublished - Jan 13 2001

Fingerprint

Vitamin E
General Practice
Aspirin
Primary Prevention
Hypercholesterolemia
Atherosclerosis
Obesity
Antioxidants
Myocardial Infarction
Hemorrhage
Hypertension
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Low-dose aspirin and vitamin E in people at cardiovascular risk : A randomised trial in general practice. / Roncaglioni, Maria Carla; Bertele, Vittorio.

In: Lancet, Vol. 357, No. 9250, 13.01.2001, p. 89-95.

Research output: Contribution to journalArticle

@article{dd4bd5397c9d4be9ad71acd5e61a1d93,
title = "Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice",
abstract = "Background: In addition to the treatment of specific cardiovascular risk factors, intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. Methods: We did a randomised controlled open 2×2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events, in people with one or more of the following: hypertension, hypercholesterolaemia, diabetes, obesity, family history of premature myocardial infarction, or individuals who were elderly. Findings: 4495 people (2583 female, mean age 64-4 years) were included in the trial. After a mean follow-up of 3-6 years the trial was prematurely stopped on ethical grounds when newly available evidence from other trials on the benefit of aspirin in primary prevention was strictly consistent with the results of the second planned interim analysis. Aspirin lowered the frequency of all the endpoints, being significant for cardiovascular death (from 1.4 to 0.8{\%}; relative risk 0.56 [95{\%} Cl 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3{\%}; 0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than the no-aspirin group (1.1{\%} vs 0.3{\%}: p",
author = "Roncaglioni, {Maria Carla} and Vittorio Bertele",
year = "2001",
month = "1",
day = "13",
doi = "10.1016/S0140-6736(00)03539-X",
language = "English",
volume = "357",
pages = "89--95",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9250",

}

TY - JOUR

T1 - Low-dose aspirin and vitamin E in people at cardiovascular risk

T2 - A randomised trial in general practice

AU - Roncaglioni, Maria Carla

AU - Bertele, Vittorio

PY - 2001/1/13

Y1 - 2001/1/13

N2 - Background: In addition to the treatment of specific cardiovascular risk factors, intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. Methods: We did a randomised controlled open 2×2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events, in people with one or more of the following: hypertension, hypercholesterolaemia, diabetes, obesity, family history of premature myocardial infarction, or individuals who were elderly. Findings: 4495 people (2583 female, mean age 64-4 years) were included in the trial. After a mean follow-up of 3-6 years the trial was prematurely stopped on ethical grounds when newly available evidence from other trials on the benefit of aspirin in primary prevention was strictly consistent with the results of the second planned interim analysis. Aspirin lowered the frequency of all the endpoints, being significant for cardiovascular death (from 1.4 to 0.8%; relative risk 0.56 [95% Cl 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3%; 0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than the no-aspirin group (1.1% vs 0.3%: p

AB - Background: In addition to the treatment of specific cardiovascular risk factors, intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. Methods: We did a randomised controlled open 2×2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events, in people with one or more of the following: hypertension, hypercholesterolaemia, diabetes, obesity, family history of premature myocardial infarction, or individuals who were elderly. Findings: 4495 people (2583 female, mean age 64-4 years) were included in the trial. After a mean follow-up of 3-6 years the trial was prematurely stopped on ethical grounds when newly available evidence from other trials on the benefit of aspirin in primary prevention was strictly consistent with the results of the second planned interim analysis. Aspirin lowered the frequency of all the endpoints, being significant for cardiovascular death (from 1.4 to 0.8%; relative risk 0.56 [95% Cl 0.31-0.99]) and total cardiovascular events (from 8.2 to 6.3%; 0.77 [0.62-0.95]). Severe bleedings were more frequent in the aspirin group than the no-aspirin group (1.1% vs 0.3%: p

UR - http://www.scopus.com/inward/record.url?scp=0035852471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035852471&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)03539-X

DO - 10.1016/S0140-6736(00)03539-X

M3 - Article

C2 - 11197445

AN - SCOPUS:0035852471

VL - 357

SP - 89

EP - 95

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9250

ER -